Role of proteasomes in disease by Dahlmann, Burkhardt
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Biochemistry
Open Access Review
Role of proteasomes in disease
Burkhardt Dahlmann
Address: Institut für Biochemie, Charité-Universitätsmedizin-Berlin, Monbijoustr. 2, 10117 Berlin, Germany
Email: Burkhardt Dahlmann - burkhardt.dahlmann@charite.de
Abstract
A functional ubiquitin proteasome system is essential for all eukaryotic cells and therefore any
alteration to its components has potential pathological consequences. Though the exact underlying
mechanism is unclear, an age-related decrease in proteasome activity weakens cellular capacity to
remove oxidatively modified proteins and favours the development of neurodegenerative and
cardiac diseases. Up-regulation of proteasome activity is characteristic of muscle wasting conditions
including sepsis, cachexia and uraemia, but may not be rate limiting. Meanwhile, enhanced presence
of immunoproteasomes in aging brain and muscle tissue could reflect a persistent inflammatory
defence and anti-stress mechanism, whereas in cancer cells, their down-regulation reflects a means
by which to escape immune surveillance. Hence, induction of apoptosis by synthetic proteasome
inhibitors is a potential treatment strategy for cancer, whereas for other diseases such as
neurodegeneration, the use of proteasome-activating or -modulating compounds could be more
effective.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Proteasome localization and function
As proteins play crucial roles in virtually all biological
processes, the finely tuned equilibrium between their syn-
thesis and degradation influences cellular homoeostasis.
Protein degradation is predominantly catalysed by the
proteasome, a giant protein breakdown enzyme complex,
any disturbance to which can result in the onset of disease
processes. The present review briefly summarizes some of
the major aspects relating to the role of proteasomes in
disease.
The majority of cellular proteins are degraded by the ubiq-
uitin proteasome system (UPS), which consists of both
substrate-recruiting and substrate-degrading machinery.
The former is composed of three enzymes, the first of
which (E1) activates the polypeptide ubiquitin in an ATP-
dependent manner, enabling its transfer onto a ubiquitin
carrier enzyme (E2). Activated ubiquitin is further trans-
ferred by a ubiquitin protein ligase (E3) to a substrate pro-
tein [1]. The substrate-recruiting machinery then catalyses
the formation of an isopeptide bond between the C-termi-
nal glycine residue of ubiquitin and the ε-amino group of
a substrate protein lysine residue. Repeated addition of
ubiquitin moieties onto the first results in a polyubiquit-
ylated substrate protein that is recognized by the proteo-
lytic machinery of the UPS, the 26S proteasome [2]. The
26S proteasome contains a central, barrel-like core parti-
cle (the 20S proteasome) composed of four stacked seven-
membered rings, with the subunit stoichiometry α1-7β1-
7β1-7α1-7[3]. A six-membered ring of AAA ATPase proteins
binds to one or both outer α-rings and, together with two
non-ATPase subunits, forms the base, while nine other
subunits comprise the adjoining lid. In turn, the base and
lid comprise the 19S regulator complex (19S REG) [4-6],
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which functions in the recognition of ubiquitylated sub-
strates and their subsequent binding [7], de-ubiquityla-
tion [8,9], unfolding and transfer into the central chamber
of the 20S proteasome [10,11]. Within the 20S proteas-
ome, subunits β1, β2, and β5 of both adjacent β-rings
expose their proteolytically active sites, exhibiting post-
glutamyl peptide hydrolysing (PGPH), trypsin-like and
chymotrypsin-like cleavage specificity, respectively
[12,13]. Under conditions of acute immune or stress
response, these three β subunits can be substituted during
de novo proteasome biosynthesis for the interferon-γ-
inducible subunits β1i, β2i, and β5i. This results in the
replacement of standard 20S proteasomes with immuno-
proteasomes, which have different cleavage specificities to
those described above [14,15]. Replacement of only one
or two of the active site-containing β subunits results in
the formation of intermediate type proteasomes [16].
Alternatively, the proteasome activator PA28 can associate
with the 20S proteasome in place of 19S REG [1].
In mammalian cells, proteasomes are located throughout
the cytoplasm though most highly concentrated at the
centrosome [18]. By contrast, immunoproteasomes spe-
cifically concentrate at the endoplasmic reticulum [19]. A
nuclear localization signal directs proteasomes to enter
the cell nucleus [20,21] (particularly after induction of
cell stress [22]), in which they accumulate in focal sub-
domains [23]. Circulating 20S proteasomes (probably
released from (dying) cells) have been found in human
plasma and could potentially be used as diagnostic mark-
ers [24-26]. In yeast cells, the majority of proteasomes
have been detected in the cell nucleus [27].
Whereas polyubiquitylation of proteins labels them for
degradation by proteasomes, monoubiquitylation confers
a cellular localization signal that, for example, directs
them from the plasma membrane to endosomes and mul-
tivesicular bodies. The monoubiquitin localization signal
also plays a role in regulating protein activity and function
[28,29].
The role of the proteasome in disease
By catalysing limited or complete degradation of proteins,
the UPS functions in many basic cellular processes such as
differentiation [30], proliferation [31], apoptosis [31],
gene transcription [32], signal transduction [33], meta-
bolic regulation [34], immune surveillance [35] and many
others [36]. Thus, the UPS is essential for development
and maintenance of all eukaryotic cells [37]. This biolog-
ical importance implies that the UPS is also inevitably
involved in patho-physiological processes resulting in the
development of many diseases, including autoimmune,
neurodegenerative and rheumatoid diseases, cancer, viral
infections and cachexia (Table 1). Many of these patho-
logical states are caused by defects in the E2 and E3
enzymes or by genomic or post-translational alterations
to proteins that affect their ubiquitylation and subsequent
susceptibility to proteasomal degradation. This in turn
leads to disruptions in biochemical reaction sequences.
Numerous reviews have summarized the UPS-associated
patho-biochemical mechanisms of these disorders [e.g.
[38-43].
The present paper summarizes knowledge of the changes
in proteasomes that lead to the triggering and develop-
ment of various diseases.
Changes in proteasome activity – a cause of 
disease development?
In comparison to most other cellular proteins, the concen-
tration of proteasomes is very high, ranging from 1 to 20
µg/mg of soluble protein [44]. As for all cellular proteins,
proteasomes have a limited lifetime and thus are continu-
ously synthesized and degraded. In HeLa cells, the half-
life of standard- and immuno-proteasomes is around 5
days and 27 hours, respectively [14].
NLVS (4-hydroxy-5-iodo-3-nitrophenylacetyl-Ala-Ala-
Phe-vinyl sulfone) is a compound that covalently binds
the threonine residues of all three active site-containing β
subunits, thus significantly reducing cellular proteasome
activity. When mice thymoma and lymphoma cells are
incubated with this compound, the residual proteasome
activity (perhaps complemented by other proteases)
ensures their survival. However, functions such as MHC
class I antigen processing and presentation are clearly
impaired by NLVS treatment [45]. This indicates that cells
contain no real surplus of proteasome activity and that
any change in the function of the complex could affect cel-
lular homoeostasis. This may not necessarily compromise
cell survival, but may be important enough to induce
pathological consequences, for example, through
impaired activation of the transcription factor NFκB,
which mediates cellular responses to the many signals
received from outside [46].
Decreased proteasomal activity and disease
An age-related decrease in proteasome activity has been
observed in different tissues including bovine eye lens
[47], rat liver [48,49], human skin and epidermal cells
[50,51], rat heart [52], human lymphocytes [53], human
fibroblasts [54], rat kidney [55], rat lung [55] and rat mus-
cle [56,57]. In all of these investigations, proteasome
activity was measured using fluorigenic peptide substrates
and PGPH activity was found to be consistently depressed
with increasing age. Only in rat liver extracts [48] was an
increase in chymotrypsin- and trypsin-like activity
observed (when measured in the presence of SDS) with
increasing age. However, when specific activity was meas-
ured in purified liver 20S proteasomes, a loss of PGPHBMC Biochemistry 2007, 8(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/8/S1/S3
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activity was observed with no change in chymotrypsin-
and trypsin-like activity [49]. Therefore, results obtained
by use of tissue extracts [48,50,52] may not reflect the
intrinsic activity of proteasomes, but in fact be influenced
by other components within the homogenate, for exam-
ple proteasome activator PA28 or 19S REG [57]. Alterna-
tively, decreased activity could be due to reduced amounts
of proteasome, as observed in aging keratinocytes [50],
but not in liver tissue of aged rats when compared with
young rats [48]. However, when the specific activity of 20S
proteasomes purified from rat liver [49], rat heart [52],
human epidermis [51] and bovine lens [47] was calcu-
lated, a loss of PGPH activity [49] or PGPH and chymot-
rypsin-like activity [51], or PGPH and trypsin-like activity
[47,52] was detected, supporting the link between intrin-
sic changes in 20S proteasomes and increasing age. In
some of the studies mentioned [49-52], a rise in the con-
centration of oxidatively modified proteins was detected
in aged donor tissue samples. Since oxidatively modified
proteins have been found to be substrates of 20S proteas-
omes [58], all of these investigations have been confined
to 20S proteasomes. The concentration of ubiquitylated
proteins was also found to be increased in aged tissue and
cells [52,53], suggesting that the activity of 26S proteas-
omes could be affected by aging in addition to 20S protea-
somes. Specifically, this was shown in human
lymphocytes of elderly donors [53], as well as in late pas-
sages of a human fibroblast cell line, which both exhibited
a significant reduction in 26S proteasome activity [54].
Accordingly, a cell model for studying aging processes has
been developed by Chondrogianni and Gonos (Institute
of Biological Research and Biotechnology, Athens,
Greece) that uses human embryonic lung fibroblasts in
which a senescence-like phenotype is induced by treat-
ment with low doses of commercially available proteas-
ome inhibitors (epoxomicin or MG132) [59].
Epoxomicin, a microbial epoxyketone, is known to react
irreversibly with all three active sites but primarily with
the β5 subunit, which exhibits chymotrypsin-like activity
[60]. Though less specific, MG132, a peptide aldehyde (Z-
Table 1: Adverse effects of the environment and aging on the proteasome system. The table summarizes diseases where proteasomes 
are known to be implicated and the impact that aging and environmental effectors could have on their development.
Disease Impairment of 
proteasomes
Proteasome population 
affected
Symptoms References
Cardiac dysfunction
- transient ischemia/
reperfusion
decreased activity 26S proteasomes apoptosis 89, 90
- pressure overload decreased activity 26S proteasomes apoptosis 68
- inclusion body myositis decreased activity 26S proteasomes, induction of 
immunoproteasome
inclusion bodies 83
134
Cataract formation decreased activity 20S proteasomes aggregation of (oxidized) 
proteins
66
Neurodegenerative 
diseases
- Alzheimer's decreased activity 20S/26S proteasomes β-amyloid plaques/tau tangles, 
neuronal loss
77
78
- Parkinson's decreased activity 20S/26S proteasomes Lewy bodies, neuronal loss 73
- amyotrophic lateral sclerosis decreased activity 20S/26S proteasomes SOD1 aggregates, motor 
neuron loss
75
- Huntington's decreased activity 20S/26S proteasomes, 
induction of 
immunoproteasome
poly-glutamine inclusions, 
neuronal dysfunction/loss
76
135
Viral infections
- HIV/adenovirus decreased expression, 
inhibition
immunoproteasomes, 20S 
proteasomes
impaired immune response 156
182
- hepatitis B inhibition 20S/26S proteasomes hepatitis 183
- HTLV activation nuclear proteasomes neurological inflammation 184
Autoimmune/rheumatoid 
diseases
- Sjogren's syndrome decreased expression subunit β1i tissue destruction 185
Cancer
- multiple myeloma
- renal carcinoma
increased activity, depressed 
expression
20S/26S proteasomes, 
immunoproteasomes
suppression of apoptosis, 
induction of proliferaton
122
142,145
Cachexia
- sepsis increased activity 20S/26S proteasomes Inflammation, muscle protein 
wasting
100
- metabolic acidosis increased activity 20S/26S proteasomes Inflammation, muscle protein 
wasting
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L-leucyl-L-leucyl-L-leucinal), is probably the most widely
used proteasome inhibitor. It reacts reversibly, primarily
with proteasome subunit β5 [61].
As aging is a progressive and irreversible (but not patho-
logical) phenomenon, a decline in proteasome activity
may be regarded as the natural answer to an age-related
decrease in the rate of protein synthesis, a process counter-
balanced by protein degradation. Therefore, it is no sur-
prise that experimental inhibition of proteasome activity
in primary neuronal cells, for example, induces impair-
ments in protein synthesis [62], especially since many
transcription factors and some translation-initiation fac-
tors, as well as ribosome biogenesis, are regulated by pro-
teasomal processing [63-65]. However, as previously
mentioned, proteasome activity may also be necessary to
remove products of other processes that become imbal-
anced during aging, such as the antioxidant response sys-
tem. For example, a lowered capacity to eliminate
oxidatively damaged proteins due to a decrease in all three
proteasome peptidase activities in eye lens nuclei favours
cataract formation in elderly individuals [66] and, in heart
muscle, reduces tolerance of the aged heart to ischemia/
reperfusion [67]. Experimental thoracic aortic constric-
tion was also found to depress proteasome activity in
mouse heart and thus favours accumulation of pro-apop-
totic proteins that later induce apoptosis and cardiac dys-
function [68].
Using fluorigenic peptide substrates, an age-related
decrease in 20S proteasome activity has been detected in
certain areas of rat, mice and marmoset brain. These espe-
cially include the substantia nigra, striatum, cerebral cor-
tex and spinal cord but not cerebellum [55,69,70],
although statistical significance of the difference in activ-
ity could depend on the interval of age chosen for the
investigations [71]. A life-long steady decrease in proteas-
ome activity is proposed to be responsible for accumula-
tion of abnormally folded proteins, formation of
inclusion bodies and development of neurodegenerative
diseases such as Alzheimer's and Parkinson's disease,
amyotrophic lateral sclerosis and Huntington's disease
[72-76].
Thus, age-related proteasomal dysfunction could be
regarded as a factor in these disease processes, which
involve the formation of plaques, filaments and aggre-
gates. Once generated, these protein inclusions have been
found to further inhibit proteasome activity and thus
amplify the formation of inclusion bodies [77-80]. Addi-
tionally, the age-related loss of antioxidant capacity affects
the proteasomal system, particularly the 26S proteasome,
which appears to be itself sensitive to oxidative inactiva-
tion [81]. The latter finding has been tested by measuring
proteasome activity in the presence and absence of ATP in
neuronal cells exposed to non-toxic doses of hydrogen
peroxide (H2O2) [82]. In either case, residual proteasomal
capacity appears unable to eliminate the aggregated and
highly oxidized proteins [83], leading to irreversible
development of neurodegenerative diseases.
Which mechanisms underlie the age-related 
attenuation of proteasome activity?
Investigations into the mechanisms underlying the
change in proteasome activity during aging are usually
performed by comparing cells and tissues from individu-
als (mostly rats) of different ages, since experimental
models mimicking the aging process are difficult to
obtain. In particular, the effect of aging on proteasome
activity cannot be mimicked by proteasome knockout
models, as they are non-viable [37].
Therefore, data summarized in this review were obtained
from studies utilising many different tissues from various
species. In most investigations into age-dependent
changes in proteasome activity, a decrease in PGPH activ-
ity was detected, while changes in chymotrypsin-like and
trypsin-like activity were not as consistent. Thus, a general
decrease in 20S/26S proteasome concentration, as found
in aging keratinocytes [50] and in a human fibroblast cell
line that was experimentally induced to senescence-like
phenotype by incubation with low dose proteasome
inhibitors [54], cannot be the general underlying mecha-
nism. Certainly, a lower concentration of subunit α4
mRNA was measured in mesencephalon of adult rats
when compared with young, suggesting an age-dependent
decreased expression of proteasomes [84]. However, if
this were the case, a general decrease in all three proteas-
ome activities catalyzed by subunits β1 (PGPH-activity, β2
(trypsin-like activity) and β5 (chymotrypsin-like activity)
should be observed during aging.
Glycation and/or conjugation with the lipid peroxidation
product 4-hydroxy-2-nonenal of several α and β subunits
(including active site-containing β subunits) was found to
coincide with a decrease in chymotrypsin-like activity of
26S proteasomes in lymphocytes from healthy 50–63 year
old human donors when compared with 20–35 year old
donors [53]. Only two subunits from the 19S REG base
were glycated without an effect on the stability and abun-
dance of 26S proteasomes [53]. This observation corrobo-
rates the finding that aging does not coincide with an
enhanced dissociation of 26S proteasomes into core 20S
particles and 19S regulators [54]. Similarly, modifications
by 4-hydroxy-2-nonenal, a peroxidation product derived
from oxidized ω-6 polyunsaturated fatty acids [85], were
found to affect neuronal proteasomes [86-88], as well as
myocardial proteasomes after coronary occlusion/reper-
fusion [89,90].BMC Biochemistry 2007, 8(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/8/S1/S3
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The chaperone Hsp90 was shown to protect 20S proteas-
omes from oxidative inactivation in rat hepatoma cells
treated with iron/ascorbate [91]. Interestingly, 20S protea-
somes were found to be associated with Hsp90 when puri-
fied from bovine lens of one month old but not of two
year old animals [47]. This suggests an age-dependent loss
of the protective agent in bovine lens, thus favouring oxi-
dation of proteins including proteasomes [92], leading to
age-related cataract formation [93]. Similar to the protea-
some, Hsp90 is essential for cell survival and therefore
this protecting function cannot be tested with Hsp90
knockout cells.
Complex alterations in the proteasome system were
found in sarcopenia of rat soleus muscle. Specifically, the
concentration of 20S proteasomes in the muscle of old
rats (29–40 months) was three-fold higher, but of signifi-
cantly lower specific activity towards fluorigenic peptide
substrates, when compared with young rats (5–12
months) [94]. This loss of activity may in part be due to
oxidative modification because it was partly rescued by
addition of the reducing agent dithiothreitol (DTT) to the
test system [95]. The three-fold increase in 20S proteas-
ome concentration led to increased ratios of 20S proteas-
omes to both PA28 proteasome activator and 19S REG in
aged rats when compared with young rats. Additionally,
the interferon-γ-inducible proteasome subunits β1i and
β5i were detected in 3–6 fold higher amounts in aged
muscle compared with young muscle. Interestingly, high
expression of β1i and β5i was also found in neurons,
astrocytes and endothelial cells of the hippocampus
region of elderly humans (mean age 70 years), but only
scarcely in that of young donors (mean age 42 years) [96].
These data suggest that during aging, intermediate-type
proteasomes and immunoproteasomes may accumulate
in muscle and brain, tissues that normally predominantly
contain standard proteasomes.
Enhanced proteasome activity and disease
Muscle atrophy due to decreased protein synthesis and
accelerated protein degradation is a hallmark of many
patho-physiological situations, examples of which are
chronic kidney diseases, type I diabetes mellitus, sepsis,
cancer cachexia and starvation. Increased expression of
proteasomes in muscle tissue has been observed in rats
suffering from NH4Cl-induced metabolic acidosis [97],
tumors [98], starvation, denervation atrophy [99], sepsis
induced by cecal ligation and puncture [100] and other
catabolic conditions [reviewed in [101]], as shown by
enhanced transcription of genes encoding proteasome
subunits and enhanced proteasomal activity towards flu-
origenic substrate proteins [100]. mRNA levels of the 19S
REG subunit Rpt1 were also found to be increased in
starving rat skeletal muscle; however, knowledge of the
adaptive mechanisms of this 26S proteasome sub-com-
plex to catabolic situations is still very limited [102].
Accelerated muscle protein breakdown in burn-injured
rats can be inhibited by the proteasome inhibitor lactacys-
tin and also by the less specific but commercially available
reversible proteasome inhibitor LLnL (N-acetyl-L-leucyl-
L-leucyl-L-norleucinal) [103], which binds to all three
active sites with different affinities [104]. The same inhib-
itors [105], as well as the commercially available proteas-
ome inhibitor PSI (N-benzyloxycarbonyl-Ile-Glu-(O-t-
butyl)-Ala-leucinal), which blocks the chymotrypsin-like
activity of proteasomes [106], prevent the sepsis-induced
increase in protein degradation in rat skeletal muscle
[107]. These data clearly demonstrate that proteasomes
are responsible for enhanced muscle protein degradation
under catabolic conditions [108,109]. However, proteas-
omes appear not to be the initiating enzymes under these
conditions, since they are not able to degrade contractile
proteins and their regulators while they are assembled
within the myofibrils that constitute the majority of mus-
cle proteins [110]. Rather, the protease caspase-3, the
activity and amount of which is increased in rat skeletal
muscle under experimental diabetes mellitus, appears to
catalyse the disassembly of myofibrils [111,112]. This
leads to the delivery of substrates to muscle-specific E3
ubiquitin protein ligases (such as atrogin-1 and MuRF1),
which prepare muscle proteins for subsequent proteaso-
mal degradation [113]. Using microarray hybridization,
the mRNAs of both E3 ligases (similar to that of several
proteasome subunits) were found to be expressed at a sig-
nificantly higher level in mice and rat skeletal muscle dur-
ing fasting, tumor bearing, chronic renal failure and
experimentally induced diabetes mellitus [114]. This sug-
gests that in some cases, compounds inhibiting caspase-3
and E3 enzymes could be more useful in the clinical man-
agement of these muscle wasting conditions than protea-
some inhibitors. However, a diminution of proteasomal
activity could still be useful, for example in preventing
degradation of IκB and thus activation of NFκB, since this
transcription factor appears to be involved in the induc-
tion of muscle atrophy [115] by possibly up-regulating
MuRF1 [116]. These findings corroborate the data referred
to earlier, which showed that treatment of rats with pro-
teasome inhibitors suppresses their muscle atrophy
induced by sepsis or burn injury [103,105,106].
A complex role for the proteasome in apoptosis is sup-
ported by the finding that inhibition of proteasome activ-
ity has pro- as well as anti-apoptotic effects [31]. The
activation of NFκB by proteasomes (through degradation
of IκB) induces the expression of anti-apoptotic members
of the BCL2 family that maintain the mitochondrial
membrane barrier [117]. Additionally, proteasomes
degrade pro-apoptotic proteins such as Bax and Bid
[118,119], the tumor suppressor p53 [120] and the nega-
tive cell cycle regulators p21 (Cip1) and p27 (Kip1)BMC Biochemistry 2007, 8(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/8/S1/S3
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[reviewed in [121]]. All of these anti-apoptotic proteaso-
mal effects are predominantly found in neoplastic and
rapidly growing cells. Therefore, a main treatment strategy
for multiple myeloma involves the induction of apoptosis
through the introduction of proteasome inhibitors such
as bortezomib and NPI-0052 into these cells [122,123].
Bortezomib (formally known as MLN341, PS-341, LDP-
341) is a dipeptide boronate (pyrazylcarbonyl-phenylala-
nyl-leucyl-boronate) originally developed at ProScript
and now distributed by Millennium Pharmaceuticals. It
binds to the N-terminal threonine hydroxyl group of the
active site-containing β5 subunit in a similar manner to
peptide aldehyde inhibitors but with a slower dissociation
rate and higher specificity, since no protease other than
the proteasome was found to be inhibited in rat [124]. As
this proteasome inhibitor was found to be active against a
broad range of tumours, it entered clinical trials and is
now used as Velcade® in clinical oncology for treatment of
multiple myeloma. NPI-0052 (Salinsporamide-A) is a
non-peptide proteasome inhibitor from the marine actin-
omycete Salinospora containing a β-lacton structure simi-
lar to that of lactacystin. It was found to irreversibly
inhibit all three proteasomal peptide cleaving activities.
This compound is being developed by Nereus Pharmaceu-
ticals and is currently in Phase I clinical trials for the
patients resistant to Velcade® treatment [125].
Referring back to the complex role of proteasomes in
apoptosis, a clear pro-apoptotic proteasomal activity was
observed in human umbilical vein endothelial cells
(HUVEC), primary thymocytes and neurons. Specifically,
BCL2 and inhibitors of apoptosis proteins (IAP) were
shown to be degraded by proteasomes, resulting in a stim-
ulation of apoptosis that could be prevented by treatment
of these cells with the proteasome inhibitors MG132 (Z-
L-leucyl-L-leucyl-L-leucinal), ALLN (Acetyl-L-Leucyl-L-
Leucyl-L-Norleucinal) or lactacystin [126-128]. MG132 is
more potent and more selective than ALLN, which was
originally used as an inhibitor of calpains, a heterogenous
family of Ca-dependent cysteine proteinases [129]. These
data indicate that therapeutic use of proteasome inhibi-
tors must therefore be based on a clear knowledge of the
underlying molecular mechanism of the disease.
Furthermore, elevated proteolytic and ATPase activity due
to increased expression of 20S proteasome and 19S REG
ATPase subunits was found to occur during developmen-
tally regulated and endogenously triggered apoptosis
[130-132].
Immunoproteasomes and disease
Transcription of the gene encoding the immunoproteas-
ome subunit β1i requires binding of the transcription fac-
tors Stat-1 and IRF-1 to the partially overlapping
interferon-consensus-sequence-2/γ-interferon-activated
sequence (ICS2/GAS) in its promoter region. Due to the
presence of interferon-stimulated response elements,
transcription and expression of β1i (as well as β5i) is
induced by γ-interferon. However, cells professionally
involved in immune surveillance, such as splenocytes and
dendritic cells, constitutively express immunoproteas-
omes due to binding of unphosphorylated and non-
dimerized Stat-1 to ICS2/GAS [133]. If, as mentioned
above, brain and muscle tissue show an age-related
increase in the concentration of immunoproteasome sub-
units, it could reflect a state of constant inflammation or
cell stress. Thus, increased concentration of immunopro-
teasomes in muscle of patients suffering from myofibrillar
myopathy and inclusion body myositis [134], as well as in
neurons of a mouse model of Huntington's disease [135],
can be regarded as a consequence of, rather than the cause
of, these diseases. Alternatively, this increased concentra-
tion could result from a potential defence mechanism,
since induction of immunoproteasome subunits was
recently shown to occur in endothelial cells by nitric oxide
(NO) via cGMP/cAMP-mediated mechanisms. The NO-
induced synthesis of immunoproteasomes protected the
cells against transferrin iron-induced oxidative stress by
regulating the level of transferrin receptor [136]. Since NO
regulates processes such as vasodilatation, neurotransmit-
tance, the immune response and apoptosis, an imbalance
in this mediator has many pathological consequences. An
NO-dependent change in the ratio of standard- to
immuno-proteasomes is thought to contribute to these
consequences [137-140]. Similarly, treatment of SH-SY5Y
neural cells with non-toxic doses (1–10 µM) of H2O2
induced not only the formation of oxidized proteins but
also synthesis of immunoproteasome subunits (detected
by western blotting and real-time RT-PCR) [82], indicat-
ing the sensitivity of the proteasome system to react and
to cope with cell stress. Such an adaptation of the protea-
some system was found to be lost in senescent human
fibroblasts, which displayed a decreased concentration in
standard proteasome subunits but retention in the immu-
noproteasome subunits β1i, β2i and β5i. In contrast to
confluent young fibroblasts, the concentration of immu-
noproteasome subunits could not be augmented by treat-
ment with γ-interferon [141].
The adverse process, namely down-regulation of immu-
noproteasomes, has been found to serve as an immune
surveillance escape mechanism in several tumor cells
[142-145], since generation of certain MHC class I-pre-
sented antigenic epitopes appears less efficient when per-
formed by standard proteasomes compared with
immunoproteasomes. Another successful oncogenic
mechanism relying on insufficient antigen processing was
observed in human cervical carcinoma and melanoma
cells that express a non-functional variant of the immuno-BMC Biochemistry 2007, 8(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/8/S1/S3
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proteasome subunit β5i, designated E1. In contrast to its
functional counterpart, designated β5i-E2, variant E1 can-
not be recruited and incorporated by the proteasome mat-
uration factor, POMP, into nascent 20S proteasomes
[146]. This defect prevents formation of immunoproteas-
omes and suppresses the generation of epitopes that elicit
a cytotoxic immune response. It is therefore not surprising
that the human immunodeficiency virus (HIV) interferes
with the antigen processing/presentation machinery of its
host cell by means of competition between HIV-tat pro-
tein and Stat-1 for binding to IRF-1, thus suppressing syn-
thesis of β2i and functional immunoproteasomes [147].
Disease targets and ligands
The three different proteolytically active sites of the 20S
proteasome use the same catalytic mechanism in which
the N-terminal threonine residue is the active nucle-
ophile. Therefore, many proteasome inhibitors that mod-
ify this threonine residue, for example aldehydes [148],
epoxyketones [149], vinyl sulfones [150], lactacystin
[151] and boronates [152], affect all three peptide bond
cleaving activities, though to differing extents due to dif-
ferent binding affinities within the substrate binding
pockets and mostly with a preference for chymotrypsin-
like activity [153]. By using more ‘site-specific’ inhibitors,
Kisselev et al.[154] found that the relative importance of
each active site for the degradative process depends on the
individual substrate. Thus, site-specific inhibitors, as long
as they are membrane permeable, could be helpful in
treating malignant neoplastic diseases other than multiple
myeloma, since proteasome-dependent processes such as
neovascularization, cell adhesion and intravasation might
be more sensitive to this type of inhibitor. Site-specific
proteasome inhibitors could also be especially useful as
immunosuppressive agents in autoimmune diseases by
modulating antigen processing and MHC class I-restricted
antigen presentation, and in retroviral infections
[155,156]. For similar purposes, compounds that specifi-
cally inhibit immunoproteasomes are conceivable [157].
In addition to the ability to permeate biological mem-
branes, proteasome-inhibiting compounds should also
exhibit low toxicity. A lead compound for the develop-
ment of non-toxic compounds could be the naturally
existing, commercially available proteasome inhibitor
PR39, a 39 amino acid peptide rich in proline and
arginine residues with antimicrobial activity. This peptide
was shown to allosterically inhibit the chymotrypsin- and
caspase-like activities of 20S proteasomes. In addition, the
N-terminal 11mer fragment of PR39, known as PR11, was
also shown to display inhibitory activity [158]. PR39
attenuates post-ischemic microvascular injuries and
inflammatory reactions [159,160] and appears to bind to
the outer α-ring of 20S proteasomes [161].
Originally, proteasome inhibitors such as bortezomib (at
the time still designated MG341) were also tested in ani-
mal models for treatment of acute and chronic inflamma-
tory reactions, for example delayed type hypersensitivity
and arthritis. Oral doses of the inhibitor effectively cured
or even suppressed allergic and inflammatory reactions
[162]. As proteasomes are involved in key signalling path-
ways regulating inflammation and sepsis [163,164], the
design of new proteasome inhibitors aimed at these
important targets would be useful in the treatment of
related diseases.
In contrast to the use of proteasome inhibitors, there are
many pathological situations characterized by a depressed
proteasomal proteolytic activity that could be ameliorated
by proteasome-activating compounds, an area of the field
that has received little attention to-date [165]. Although
the exact mechanism of the age-related decrease in protea-
some activity is unknown, proteasome-activating hydro-
phobic peptides have been found that most probably
bind as modifiers at non-catalytic sites, thus mimicking
the effect of the proteasome activator PA28 by opening
the gated α-ring pore [166]. These peptides and other
compounds that were shown to activate 20S proteasomes
such as fatty acids, phosphatidyl-glycerol and di-phos-
phatidyl-glycerol [167], could be used as starting points
for generating proteasome activating compounds.
Next Frontiers
Although a great deal has been published about changes
in proteasome activity and their possible involvement in
the development of diseases, there are clear gaps in our
knowledge of the definite molecular mechanisms that
underlie these alterations. This holds especially true with
regard to the fact that proteasomes in various cells and tis-
sues are not a multitude of identical 20S proteasomes but
a mixture of several proteasome subpopulations (stand-
ard- and immuno-proteasomes) and intermediates of
each subpopulation [16,168], which have different sub-
strate specificities [16]. The distribution within the differ-
ent cell compartments of these subpopulations and the
proportions of the various proteasome complexes, for
example 26S proteasomes, hybrid proteasomes and pro-
teasome–PA28 complexes are only scarcely known. Addi-
tionally, knowledge of the molecular differences between
the various proteasome subtypes, which appear to have
different susceptibilities to inhibitors [A. Kloß and B.
Dahlmann, unpublished observation] is only superficial
[169]. These aspects, along with post-translational modi-
fications such as phosphorylation, O-GlcNAc addition
and others [170,171] that affect proteasome activity, need
to be investigated intensively with regard to disease-
related alterations to the proteasome system. Since the
proteasome is considered to be a therapeutic target, this
knowledge will also help to design more specific andBMC Biochemistry 2007, 8(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/8/S1/S3
Page 8 of 12
(page number not for citation purposes)
probably more effective compounds that modulate its
activity.
It is clear that modulation of proteasome activity is prima-
rily aimed at inhibiting the complex's proteolytic func-
tions. However, the finding that the association between
19S REG and 20S proteasomes is regulated by a proteaso-
mal ATPase-associated factor provides another promising
aspect to explore in the search for compounds that mod-
ulate proteasome activity [172]. To mimic or inhibit the
activity of this factor might help to tune the activity of
20S/26S proteasomes without risking a complete shut off
of this essential system. Similarly, compounds modulat-
ing the ATPase activity of the 19S regulator, as well as its
polyubiquitin-binding ability, could be considered for
therapeutic use.
A completely different aspect for future research with
regard to the benefit of proteasome inhibitors is based on
the finding that inhibition of proteasomal activity induces
de novo synthesis of proteasomes [173]. This knowledge
may be applicable to situations where disease processes
appear to be based on reduced amounts of, or defects in,
proteasomes, for example as occur during aging. Simi-
larly, treatment of endothelial cells with low, non-toxic
doses of the proteasome inhibitor MG132 was found to
activate an antioxidant defence programme that included
up-regulation of endothelial nitric oxide synthase
(eNOS), glutathione peroxidase-3, glutathione S-trans-
ferase and others, resulting in an improvement in
endothelial functions [174,175]. Recognition of this effect
is not only promising in the search for treatments for
patients suffering from atherosclerosis and coronary heart
diseases, but also to provide a possible measure for pre-
venting these diseases and others such as neurodegenera-
tion [176]. Based on the same biochemical background,
vascular endothelial dysfunction and neuronal death after
embolic stroke were found to be restricted and terminable
in animal models after proteasome inhibitors such as
bortezomib [177,178] or MLN519 [179] were adminis-
tered within a certain therapeutic window of a few hours
post-stroke. MLN519 ((1R-[1S,4R,5S])-1-(1hydroxy-2-
methylpropyl-6-oxa-2-azabi-cyclo [3.2.1] heptane-3,7-
dione) is a synthetic analog of lactacystin developed by
Millennium Pharmaceuticals and already tested in phase
I clinical trials [180]. An exact knowledge of the suscepti-
bility of the different forms of proteasomes to this and
other inhibitors will help to develop optimal treatments
and therapies for a wide range of diseases.
Finally, aside from proteasome inhibitors or activators,
proteasomes per se could be useful as diagnostic and even
prognostic markers, since the level of circulating proteas-
omes reflects the state of health of patients suffering from
cancer and autoimmune diseases [181].
Abbreviations used
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